Can a single drug shrink nasal polyps and restore breathing?

NCT ID NCT04607005

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether mepolizumab, an injectable drug, can reduce nasal polyp size and improve symptoms like nasal blockage in adults with chronic rhinosinusitis and nasal polyps. Participants receive either mepolizumab or a placebo every four weeks for a year. The study aims to see if the drug offers a better way to control this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an injectable drug called mepolizumab
What this could lead to
If it works, this could offer a new treatment option for people with nasal polyps that are hard to manage with standard care.
What could go wrong
This is an early-phase trial, so the drug may not prove effective or could cause side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • GSK Investigational Site

    Chiba, 262-0015, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.